Open House - Global Healthcare 2022: VolitionRx Limited | Edison Group

Open House - Global Healthcare 2022: VolitionRx Limited | Edison Group

Broadcast on: January 27, 2022
Duration: 11:08

VolitionRx Limited manufactures epigenetic cancer detection blood tests. The Company’s tests are designed to detect the nucleosome patterns that are specific to cancer in the blood and identify some of the major nucleosome varieties that differ between cancer types.

  • President and Group Chief Executive Officer

    Cameron Reynolds, President and Group Chief Executive Officer, Volition

    Cameron is the President and Group Chief Executive Officer of Volition and was one of the founders of the company in 2010. He is an experienced entrepreneurial executive, with expertise in a wide range of fields, including several biotechnology companies and has led Volition through the research and development of Volition’s proprietary Nucleosomics™ to the commercialization of its first test, the Nu.Q™ Vet Cancer Screening Test. Cameron has extensive experience in the management, structuring, and financing of start-up companies and has held positions including Chief Executive Officer, Chief Financial Officer, Chairman, and Non-Executive Director of public and private enterprises. Cameron was educated at the University of Western Australia receiving both a Bachelor of Commerce and an MBA.

More from OETV

What's happening on OETV

No upcoming videos or events

We didn't find any upcoming videos or events in your selected timeframe. Change your timeframe or check back soon for more!

No upcoming videos or events

We didn't find any upcoming videos or events in your selected timeframe. Change your timeframe or check back soon for more!

X

We value your privacy

This website or its third party tools uses cookies, which are necessary for its functioning and required to achieve the purpose illustrated in our Privacy Policy. By clicking "Accept" or dismissing this notice, you agree to our website's use of cookies.